Table 1.
Estimates of population size, disease rates, case-fatality rates, and associated costs*
| Age/risk profile | Sources | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18–49 years | 50–64 years | 65–74 years | 75–84 years | ≥ 85 years | ||||||||||||
| Low | High | Immuno-comp. | Low | High | Immuno-comp. | Low | High | Immuno-comp. | Low | High | Immuno-comp. | Low | High | Immuno-comp. | ||
| No. of Canadian adults in: | 10.4 | 4.7 | 0.3 | 4.0 | 2.9 | 0.5 | 1.4 | 1.3 | 0.3 | 0.7 | 0.7 | 0.2 | 0.3 | 0.3 | 0.1 | Statistics Canada (2013), NHIS (2012) |
| Annual disease incidenceb (per 100 K) | Demczuk et al. (2013), Rudnick et al. (2013), Kellner et al. (2009), Kyaw et al. (2005), McNeil et al. (2012), Chiltern/OXON Report on file | |||||||||||||||
| Bacteremia | 0.9 | 7.0 | 47.5 | 2.7 | 13.4 | 58.8 | 3.8 | 14.4 | 54.0 | 4.4 | 13.5 | 38.9 | 4.6 | 12.7 | 28.7 | |
| Meningitis | 0.05 | 0.37 | 2.50 | 0.14 | 0.70 | 3.09 | 0.20 | 0.76 | 2.84 | 0.23 | 0.71 | 2.05 | 0.24 | 0.67 | 1.51 | |
| ACP | McNeil et al. (2012, 2014a, b), Griffin et al.(2013), Marrie and Huang (2005), Kyaw (2005), Chiltern/OXON Report on file | |||||||||||||||
| Inpatient | 47 | 326 | 1974 | 108 | 477 | 2121 | 252 | 885 | 3329 | 590 | 1842 | 5952 | 913 | 2729 | 8181 | |
| Outpatient | 45 | 323 | 2109 | 88 | 431 | 2032 | 152 | 568 | 2250 | 276 | 873 | 2842 | 308 | 898 | 2506 | |
| Annual mortality/case-fatality (per 100) | ||||||||||||||||
| Bacteremia | 6.9 | 8.7 | 10.4 | 10.6 | 13.3 | 15.9 | 13.6 | 17.0 | 20.4 | 17.6 | 22.0 | 26.4 | 46.4 | 57.9 | 69.5 | McNeil et al. (2014a, b), Statistics Canada (2013), NHIS (2012), Smith et al. (2008), Lexau et al. (2005), Robinson et al. (2001) |
| Meningitis | 6.9 | 8.7 | 10.4 | 10.6 | 13.3 | 15.9 | 13.6 | 17.0 | 20.4 | 18.1 | 22.6 | 27.1 | 50.3 | 62.9 | 75.4 | |
| ACP requiring inpatient care | 3.4 | 4.3 | 5.2 | 6.7 | 8.4 | 10.1 | 8.6 | 10.8 | 13.0 | 11.6 | 14.5 | 17.4 | 17.8 | 22.3 | 26.7 | |
| Medical care costs (per case) | Chiltern/OXON Report on file | |||||||||||||||
| Requiring inpatient care | ||||||||||||||||
| Bacteremia | $44,747 | $54,174 | $55,061 | $44,627 | $50,514 | $58,934 | $33,023 | $44,980 | $46,954 | $35,465 | $41,857 | $46,355 | $33,487 | $45,442 | $42,628 | |
| Meningitis | $25,604 | $30,998 | $31,505 | $25,535 | $28,904 | $33,721 | $22,960 | $31,273 | $32,645 | $24,658 | $29,101 | $32,229 | $23,282 | $31,594 | $29,638 | |
| ACPc | $14,605 | $16,556 | $21,403 | $14,098 | $16,001 | $21,845 | $17,347 | $19,750 | $25,591 | $16,555 | $20,234 | $24,665 | $16,691 | $20,537 | $23,294 | |
| Requiring outpatient care only | ||||||||||||||||
| ACP | $96 | $98 | $113 | $95 | $97 | $112 | $95 | $96 | $112 | $94 | $96 | $111 | $94 | $96 | $111 | Morrow et al. (2007) |
| Vaccination (per person) |
Proactive Pharma Solutions 2014d Pfizer Canada Skowronski et al. (2006) |
|||||||||||||||
| PPV23 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | $11.00 | |
| PCV13 | Confidential Contact price | |||||||||||||||
| Administration | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | $15.59 | |
NHIS: National Health Interview Survey
aEstimates correspond to mid-point of age range
bRates in year 5 of modeling horizon, fully adjusted for herd effects
cUnit cost was assumed to be the same for all cases of ACP, irrespective of the causative pathogen (see supplement material for more details)
dThe price of PPV23 was set at $11.00 per dose, which was based on 2016 IMS data and an assumed discount to approximate the confidential government contract price